Ayahuasca
Other names:
- Chacruna (for the Psychotria viridis plant)
- Hoasca (tea)
- Yajé
Basics: Ayahuasca is the Quechua name for a vine, Banisteriopsis caapi, and also for a brew made by combining the vine with leaves of plants, usually the Amazonian shrub Psychotria viridis, which contains N,N-dimethyltryptamine (DMT). On its own, DMT won’t produce psychedelic effects if taken orally, because the molecule is deactivated primarily in the gut by an enzyme called monoamine oxidase. But Banisteriopsis caapi contains monoamine oxidase inhibitors (MAOIs), which keep that enzyme from destroying DMT, allowing the psychoactive molecules to reach the brain. The effect profile of ayahuasca overlaps with that of the classic psychedelics generally. For some people, there is an enhanced likelihood of visions. The experience usually begins about thirty minutes after drinking the tea and continues for roughly four hours.
History: Ayahuasca has been used for over a thousand years by Indigenous people in Brazil, Peru, Bolivia, Colombia, and Ecuador in shamanic practices and to help with the diagnosis or treatment of various medical, psychological, or spiritual conditions.
In the twentieth century, the Santo Daime and the União do Vegetal religions emerged in Brazil. These syncretic traditions, which fuse aspects of Indigenous religions with Christianity, mysticism, and other influences, use ayahuasca as a sacrament during ceremonies.
Potential Benefits: Like other classic psychedelics, ayahuasca can cause visual and auditory distortions or changes; hypersensitivity to touch, light, and sound; an altered or slowed perception of time; and synesthesia.
Potential Risks and Side Effects: Ayahuasca can cause shaking, vomiting, and diarrhea and can significantly raise blood pressure. It can have adverse reactions with medications including selective serotonin reuptake inhibitors. It has also been shown to exacerbate psychiatric disorders, including schizophrenia.
Therapy: Research suggests that ayahuasca could be used in carefully structured settings to treat addiction, depression, and anxiety. Some users report that after taking ayahuasca they feel more creative, loving, and empathetic; see improvement in their memory and concentration; and generally have a more positive mood. Long-term use of ayahuasca has been shown to produce changes in brain chemistry and personality.
Legality: Ayahuasca therapy and ayahuasca use are illegal in the United States because DMT, its main active ingredient, is a Schedule I controlled substance, though exemptions under the Religious Freedom Restoration Act have been granted. A 2006 Supreme Court decision cleared the way for the União do Vegetal to use ayahuasca in its religious practices. In 2009, an Oregon judge granted a similar exemption to Church of the Holy Light of the Queen, an Ashland, Oregon, congregation in the Santo Daime tradition.
Notable Studies:
- A small, double-blind, randomized, placebo-controlled trial found that in an appropriate setting, ayahuasca can cause significant and rapid positive improvement in patients with treatment-resistant depression.
- A larger, meta-review that found psilocybin, ayahuasca, and LSD could be effective treatments for drug dependence and anxiety and mood disorders.
- Interviews with Western mental health professionals and Indigenous healers who both use ayahuasca suggest ayahuasca can help treat addiction and a survey found ayahuasca users reported less problematic alcohol consumption.
- A study on the long-term effects of ayahuasca found that it may enhance neuroplasticity and structurally change parts of the default mode network.
Selected Sources
Ayahuasca: Uses, Phytochemical and Biological Activities
Natural Products and Bioprospecting, 2019
Therapeutic Effects of Ritual Ayahuasca Use in the Treatment of Substance Dependence—Qualitative Results
Journal of Psychoactive Drugs, 2014
Ayahuasca: Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental Illness
Current Neuropharmacology, 2019
Long-term use of psychedelic drugs is associated with differences in brain structure and personality in humans
European Neuropsychopharmacology, 2015
Gonzales v. O Centro Espírita Beneficente União do Vegetal
U.S. Supreme Court, 2006
More to Read
Classic Psychedelics
5-MeO-DMT
Classic Psychedelics
DMT
Classic Psychedelics
LSD
Classic Psychedelics
Mescaline
Classic Psychedelics
Psilocybin
Non-Classic Psychedelics
Ibogaine
Non-Classic Psychedelics
Ketamine
Non-Classic Psychedelics
MDMA
Non-Classic Psychedelics